Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention

Journal of Managed Care Pharmacy

Volumn 21, Issue 7, 2015, Pages 552-557

  Johnson, Samuel G ^a,b   Gruntowicz, Don ^c,d,e   Chua, Theresa ^a   Morlock, Robert J ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b KAISER PERMANENTE   (United States)

^c Genelex Corporation   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f YourCareChoice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; CORONARY STENT; GENOTYPE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICATION COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG COMBINATION; ECONOMICS; GENETIC SCREENING; GENETICS; HEALTH INSURANCE; PROCEDURES; STATISTICAL MODEL; THROMBOSIS;

ACUTE CORONARY SYNDROME; ADENOSINE; CYTOCHROME P-450 CYP2C19; DRUG THERAPY, COMBINATION; GENETIC TESTING; GENOTYPE; HUMANS; MANAGED CARE PROGRAMS; MODELS, ECONOMIC; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; THROMBOSIS; TICLOPIDINE;

EID: 84934755211     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.7.552     Document Type: Article

References (26)

1. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics:challenges on the road to the clinic. PLoS Med.2007;4(8):e209.
2. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med.2011;13(12):987-95.
3. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-30.
4. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med.2009;360(4):354-62.
5. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704-14.
6. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-23.
7. U.S. Food and Drug Administration. FDA announces new boxed warning on Plavix. FDA News Release. March 12, 2010. Available at: http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204253.htm. Accessed May 9, 2015.
8. Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160(4):221-32.
9. Personalized Medicine Coalition. The case for personalized medicine. 4th ed. 2014. Available at: http://www.personalizedmedicinecoalition.org/ Userfiles/PMC-Corporate/file/pmc_case_for_personalized_medicine.pdf. Accessed May 9, 2015.
10. Lala A, Berger JS, Sharma G, Hochman JS, Scott BR, Ladapo JA. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost.2013;11(1):81-91.
11. Reese ES, Daniel MC, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy. 2012;32(4):323-32.
12. Sorich MJ, Coory M, Pekarsky BA. Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. PLoS One.2013;8(8):e72256.
13. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.2007;357(20):2001-15.
14. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
15. Johnston SS, Curkendall S, Makenbaeva D, et al. The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med.2011;53(1):2-7.
16. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med.2011;154(1):1-11.
17. Wiegand PN, Wertheimer AI. An economic evaluation of anticipated costs and savings of a behavior change intervention to enhance medication adherence. Pharm Pract (Granada).2008;6(2):68-73.
18. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705-11.
19. Ferreri SP, Greco AJ, Michaels NM, et al. Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003).2014;54(2):172-80.
20. Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther.2012;92(2):235-42.
21. Montouchet C, Ruff L, Balu S. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a U.S. managed care perspective.J Med Econ.2013;16(7):907-16.
22. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73-83.
23. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes.2009;2(5):429-36.
24. Blich M, Zeidan-Shwiri T, Petcherski S, Osherov A, Hammerman H. Incidence, predictors and outcome of drug-eluting stent thrombosis in realworld practice. J Invasive Cardiol.2010;22(10):461-64.
25. Ray T. Lawsuit in Hawaii against Plavix sponsors alleges burden is on pharma to market PGx information. April 16, 2014. Available at: http://www. genomeweb.com/clinical-genomics/lawsuit-hawaii-against-plavix-sponsorsalleges- burden-pharma-market-pgx-informat. Accessed May 10, 2015.
26. Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123(24):2819-28.